Alexander C. Egilman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander C. Egilman has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Solomon Ross
Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
3 shared publications - Audrey D. Zhang
Department of General Medicine, Beth Israel Deaconess Medical Center , Boston, Massachusetts
2 shared publications - Benjamin N. Rome
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
2 shared publications Aaron S. Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
1 shared publication- Aaron Seth Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
1 shared publication - Ameet Sarpatwari
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
1 shared publication
Latest Publications
- 14 July 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70012
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top‐Selling Drugs
Objective: To examine whether the new Medicare inflation rebate policy was associated with changes in manufacturer pricing behavior. Study Setting and Design: In this cross‐sectional study of 156 top‐selling brand‐name drugs, we used linear regression to evaluate whether there was an association between drugs' exposure to the policy (i.e., Medicare's share of net US sales) and differences in year‐over‐year price changes before (2021–2022) versus after (2022–2023, 2023–2024) the policy took effect. Data Sources and Analytic Sample: The study used Medicare spending data and average sales prices from the Centers for Medicare and Medicaid Services, wholesale acquisition costs from Eversana NAVLIN's Price & Access database, and sales revenue and estimated rebates from SSR Health. Vaccines, biosimilars, drugs approved after 2020, and those with generic or biosimilar competition before 2023 were excluded. Drugs were stratified by whether they derived most sales from Medicare Part B or Part D. Principal Findings: The median Medicare share of net sales was 28% (IQR: 18%–37%) for 50 Part B drugs and 32% (IQR: 16%–49%) for 106 Part D drugs. Median year‐over‐year price changes in 2021–2022, 2022–2023, and 2023–2024 were 3.2%, 2.9%, and 3.4% for Part B drugs and 5.0%, 5.9%, and 4.9% for Part D drugs. There was no association between drugs' Medicare share of net sales and differences in price changes pre‐ vs. post‐policy for Part B drugs (2023: p = 0.99; 2024: p = 0.09). For Part D drugs, each 10% increase in drugs' share of Medicare sales was associated with a 0.18% (95% CI, 0.01%–0.35%, p = 0.04) higher price change in the first year after policy implementation; there was no significant association in the second year ( p = 0.17). Conclusions: Medicare inflation rebates were not associated with smaller price increases among the top‐selling drugs most affected by the policy. Additional measures are needed to prevent drug manufacturers from raising prices each year, such as extending inflation rebates to commercially insured patients.
- 14 July 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70012
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top‐Selling Drugs
Objective: To examine whether the new Medicare inflation rebate policy was associated with changes in manufacturer pricing behavior. Study Setting and Design: In this cross‐sectional study of 156 top‐selling brand‐name drugs, we used linear regression to evaluate whether there was an association between drugs' exposure to the policy (i.e., Medicare's share of net US sales) and differences in year‐over‐year price changes before (2021–2022) versus after (2022–2023, 2023–2024) the policy took effect. Data Sources and Analytic Sample: The study used Medicare spending data and average sales prices from the Centers for Medicare and Medicaid Services, wholesale acquisition costs from Eversana NAVLIN's Price & Access database, and sales revenue and estimated rebates from SSR Health. Vaccines, biosimilars, drugs approved after 2020, and those with generic or biosimilar competition before 2023 were excluded. Drugs were stratified by whether they derived most sales from Medicare Part B or Part D. Principal Findings: The median Medicare share of net sales was 28% (IQR: 18%–37%) for 50 Part B drugs and 32% (IQR: 16%–49%) for 106 Part D drugs. Median year‐over‐year price changes in 2021–2022, 2022–2023, and 2023–2024 were 3.2%, 2.9%, and 3.4% for Part B drugs and 5.0%, 5.9%, and 4.9% for Part D drugs. There was no association between drugs' Medicare share of net sales and differences in price changes pre‐ vs. post‐policy for Part B drugs (2023: p = 0.99; 2024: p = 0.09). For Part D drugs, each 10% increase in drugs' share of Medicare sales was associated with a 0.18% (95% CI, 0.01%–0.35%, p = 0.04) higher price change in the first year after policy implementation; there was no significant association in the second year ( p = 0.17). Conclusions: Medicare inflation rebates were not associated with smaller price increases among the top‐selling drugs most affected by the policy. Additional measures are needed to prevent drug manufacturers from raising prices each year, such as extending inflation rebates to commercially insured patients.
- 1 June 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (6) , 833-835
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label
- 1 June 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (6) , 833-835
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label
- Open Access
Clinical Trial Data Sharing: A Cross-Sectional Study of Outcomes Associated with Two NIH Models
Background The impact and value of clinical trial data sharing, including the number and quality of publications that result from shared data – “shared data publications” – may differ depending on the data sharing model used. Methods We characterized the outcomes associated with two data sharing models previously used by Institutes of the U.S. National Institutes of Health (NIH): NHLBI’s centralized model, which uses a repository to manage data sharing requests, and NCI’s decentralized model, which entrusted research groups to independently manage data sharing requests. We identified trials completed in 2010 that met NIH data sharing criteria and matched studies sponsored by each Institute based on cost or size, determining whether trial data were shared and the frequency of shared data publications. Results We identified 14 NHLBI-funded trials and 48 NCI-funded trials that met NIH data sharing criteria. We matched 14 NCI-funded trials to the 14 NHLBI-funded trials; among these, 4 NHLBI-sponsored trials (29%) and 2 NCI-sponsored trials (14%) shared data. From the 2 NCI-sponsored trials sharing data, we identified 2 shared data publications, one per trial, both of which were meta-analyses. From the 4 NHLBI-sponsored trials sharing data, we identified 7 shared data publications, all using data from 1 trial, 5 of which were pooled analyses and 2 reported secondary outcomes. Conclusion When characterizing the outcomes associated with two NIH data sharing models, both the NHLBI and the NCI models resulted in only 21% of trials sharing data and few shared data publications. There are opportunities to optimize clinical trial data sharing efforts both to enhance clinical trial data sharing and increase the number of shared data publications.
Open AccessClinical Trial Data Sharing: A Cross-Sectional Study of Outcomes Associated with Two NIH Models
Background The impact and value of clinical trial data sharing, including the number and quality of publications that result from shared data – “shared data publications” – may differ depending on the data sharing model used. Methods We characterized the outcomes associated with two data sharing models previously used by Institutes of the U.S. National Institutes of Health (NIH): NHLBI’s centralized model, which uses a repository to manage data sharing requests, and NCI’s decentralized model, which entrusted research groups to independently manage data sharing requests. We identified trials completed in 2010 that met NIH data sharing criteria and matched studies sponsored by each Institute based on cost or size, determining whether trial data were shared and the frequency of shared data publications. Results We identified 14 NHLBI-funded trials and 48 NCI-funded trials that met NIH data sharing criteria. We matched 14 NCI-funded trials to the 14 NHLBI-funded trials; among these, 4 NHLBI-sponsored trials (29%) and 2 NCI-sponsored trials (14%) shared data. From the 2 NCI-sponsored trials sharing data, we identified 2 shared data publications, one per trial, both of which were meta-analyses. From the 4 NHLBI-sponsored trials sharing data, we identified 7 shared data publications, all using data from 1 trial, 5 of which were pooled analyses and 2 reported secondary outcomes. Conclusion When characterizing the outcomes associated with two NIH data sharing models, both the NHLBI and the NCI models resulted in only 21% of trials sharing data and few shared data publications. There are opportunities to optimize clinical trial data sharing efforts both to enhance clinical trial data sharing and increase the number of shared data publications.
- 15 June 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (10) , 3281-3284
Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
- 15 June 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (10) , 3281-3284
Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
- 1 October 2019
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 171 (7) , 521-523
Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors
- 1 October 2019
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 171 (7) , 521-523
Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors